IL6 and breast carcinoma: Additionally, AFI has been reported to have anticancer activities against human breast cancer cells (MCF-7) and lung cancer cells (HCC827) by stimulating the production of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) (34).